The young CBD industry is growing accustomed to federal health authorities warning companies not to make medical claims about the cannabinoid.
But a round of warning letters this week from the U.S. Federal Trade Commission (FTC) – the consumer-protection agency that safeguards against unfair and deceptive advertising – served as a reminder that as CBD goes mainstream, more federal agencies are giving the industry a critical look.
This week’s FTC warnings went to three unidentified CBD companies. Among other complaints, the FTC criticized the businesses for:
- Posting on a website that CBD “works like magic.”
- Advertising CBD as a “miracle pain remedy.”
- Touting a CBD cream’s ability to relieve arthritis pain.
- Using a partnership with Harvard University researchers to bolster claims that CBD has been “clinically proven to treat cancer, Alzheimer’s disease, multiple sclerosis, fibromyalgia, cigarette addiction and colitis.”